NHS England updates CDF List
NHS England updates CDF List
NHS England has updated the Cancer Drugs Fund List. The latest version (v1.363) was uploaded to the NHS England Website on Friday 16, May 2025.
The following changes have been introduced:
Selpercatinib (SEL1)
For the treatment of adults or adolescents aged 12 years and older with previously treated RET fusion positive non-medullary thyroid cancer where the following criteria have been met
Moved into routine commissioning - section B of list
Selpercatinib (SEL5)
For the treatment of adults and adolescents aged 12 years and older with RET fusion positive non-medullary thyroid cancer previously UNTREATED with any kinase inhibitor therapy where the following criteria have been met
Moved into routine commissioning - section B of list
Asciminib (ASC1)
For the treatment of patients with chronic phase Philadelphia chromosome-positive chronic myeloid leukaemia previously treated with two or more tyrosine kinase inhibitors where the following criteria have been met
Treatment criteria (#6 and 14) updated
Blinatumomab (BLI1)
The treatment of relapsed/refractory Philadelphia negative B-precursor acute lymphoblastic leukaemia in ADULT patients
Treatment criteria (#1, 6, 8 and 10) updated
Blinatumomab (BLI2)
The treatment of relapsed/refractory Philadelphia negative B-precursor acute lymphoblastic leukaemia in CHILD patients
Treatment criteria (#1, 2, 6, 9, 10 and 12) updated
Nivolumab (NIV1)
Nivolumab for previously treated advanced renal cell carcinoma
Treatment criteria (#6 and 8) updated
Nivolumab (NIV6)
The treatment of recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum-based chemotherapy where all the following crtieria are met:
Treatment criteria (#8 and 11) updated
Darolutamide in combination with docetaxel and androgen deprivation therapy (ADT) (DARO2)
For the treatment of patients with newly diagnosed metastatic hormone-sensitive prostate cancer where the following criteria have been met
Title updated
Erdafitinib (ERD1)
Erdafitinib for unresectable locally advanced or metastatic urothelial carcinoma which has a susceptible fibroblast growth factor receptor 3 (FGFR3) genetic alteration in patients previously treated with at least one line of therapy containing a PD-1 or PD-L1 inhibitor administered in the unresectable locally advanced or metastatic treatment setting where the following criteria have been met
Date moving into routine commissioning updated